- Bausch Health Companies' full-year revenue was US$ 8.4 billion for 2021, representing an increase of five per cent year-over-year (YoY).
- During the trading session on Wednesday, February 23, the BHC stock declined 3.3 per cent and closed at C$ 29.16 per share.
- In 2022, Bausch Health Companies expects to clock revenues in the range of US$ 8.4 to US$ 8.6 billion.
Bausch Health Companies Inc. (TSX:BHC) announced fourth quarter fiscal 2021 and provided guidance for this year. In Q4 2021, total reported revenues of Bausch Health Companies were US$ 2,196 billion compared to US$ 2,213 billion in the fourth quarter of 2020.
During the trading session on Wednesday, February 23, the BHC stock declined 3.3 per cent and closed at C$ 29.16 per share.
Bausch Health Companies' full-year revenue was US$ 8.4 billion for 2021, representing an increase of five per cent year-over-year (YoY). The overall increase in revenue for the year was due to a 10 per cent YoY growth in revenues of Bausch + Lomb segment.
Financial performance of Bausch Health Companies (TSX:BHC)
According to some analysts, the revenues of Bausch Health Companies for Q4 2021 fell short of expectations. Meanwhile, net income for Q4 2021 was US$ 69 million against a net loss of US$ 153 million in the same comparable quarter of 2020.
In 2021, Bausch Health repaid its debt worth US$ 1.3 billion and used the cash from operations and divestiture of Amoun Pharmaceutical Company S.A.E.
©2022 Kalkine Media®
The operating income of Bausch Health Companies was US$ 367 million in Q4 2021 compared to an operating loss of US$ 5 million in Q4 2020.
In 2021, the company generated a cash of US$ 1.43 billion, an increase of US$ 315 million from 2020. Meanwhile, the adjusted EBITDA rose to US$ 3.5 billion last year, up from US$ 3.3 billion in 2020.
In 2022, Bausch Health Companies expects to clock revenues in the range of US$ 8.4 to US$ 8.6 billion and full-year adjusted EBITDA between US$ 3.45-US$ 3.6 billion.
Apart from providing the full-year guidance, the company revealed some other significant development, which included receiving approval from the Food and Drug Administration for a New Drug Application (NDA) for XIPERE.
Bausch Health Companies has partnered with Lochan LLC to develop eyeTELLIGENCE®, the next-generation clinical decision support software.
In Jordan and South Korea, the company received regulatory approval for LUMIFY, an eye drop for reducing the redness in the eyes.
Please note, the above content constitutes a very preliminary observation or view based on market trends and is of limited scope without any in-depth fundamental valuation or technical analysis. Any interest in stocks or sectors should be thoroughly evaluated taking into consideration the associated risks.